NRC Health (NRC) reported $137M in revenue for fiscal 2025, −4.0% year on year. That ranks #2820 by revenue among 2853 SEC filers and #315 in Healthcare. Net income was $11.6M, a net margin of 8.4%. Revenue has grown 4.3% a year on average since 2011 ($75.8M then). The fiscal 2025 balance sheet shows $135M in total assets, $4.1M in cash and $75.0M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $137M | −4.0% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $22.6M | −35.8% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $11.6M | −53.2% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $26.5M | −23.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $10.7M | −30.7% | FY20252025-12-31 |
| Total assetsAssets | $135M | +1.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $14.0M | −55.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $4.1M | −2.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $75.0M | +29.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $34.8M | $3.2M | Open → |
| Q2 20262026-06-30 | $35.4M | −$3.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- NRC Health
- Ticker
- NRC
- Exchange
- Nasdaq
- SIC classification
- Services-Commercial Physical & Biological Research (8731)
- Fiscal year end
- 12-31
- CIK
- 0000070487
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KMar 5, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Karyopharm TherapeuticsKPTI | $146M | −$196M |
| Infusystem HoldingsINFU | $143M | $6.6M |
| Beam TherapeuticsBEAM | $140M | −$80.0M |
| NRC HealthNRC | $137M | $11.6M |
| RxsightRXST | $134M | −$38.9M |
| Xtant MedicalXTNT | $134M | $4,973 |
| RidgetechRDGT | $132M | −$1.3M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=NRC Health — Key figures |url=https://companiesranked.com/en/company/nrc-health |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). NRC Health — Key figures. CompaniesRanked. https://companiesranked.com/en/company/nrc-healthBibTeX
@misc{companiesranked-en-company-nrc-health-2026,
author = {{CompaniesRanked}},
title = {{NRC Health — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/nrc-health}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001437749-26-007002 · March 5, 2026
{{cite web |title=NRC Health — Key figures — 10-K (0001437749-26-007002) |url=https://www.sec.gov/Archives/edgar/data/70487/000143774926007002/nrc20251231_10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-05}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.